Printer Friendly

IMMUNEX FILES LEUKINE LICENSE AMENDMENT

 SEATTLE, March 31 /PRNewswire/ -- Immune~ Corp. (NASDAQ: IMNX) announced today that it has submitted a product license amendment to the Food and Drug Administration (FDA) to use LEUKINE(R) (Sargramostim) for the prophylaxis and treatment of chemotherapy-induced neutropenia, an abnormally low white blood cell level.
 LEUKINE is a white blood cell stimulant used to speed recovery of cancer patients undergoing autologous bone marrow transplantation and to improve survival of cancer patients whose bone marrow transplants have failed. The company's application for an expanded product label includes safety and efficacy data from studies of patients who received Sargramostim to accelerate neutrophil recovery after undergoing a variety of cancer chemotherapy regimens.
 Each year approximately 225,000 cancer patients receive chemotherapy that is destructive not only to cancer cells but to certain immune cells as well, making these patients vulnerable to life-threatening infections. LEUKINE is one of a group of proteins called colony stimulating factors which regulate the production of different types of blood cells and which may reduce neutropenia in cancer patients who receive myelosuppressive chemotherapy.
 Immunex is currently investigating the therapeutic potential of LEUKINE in a variety of indications, including peripheral blood stem cell mobilization and infectious disease.
 Immunex is a biopharmaceutical company focused on the discovery, development, manufacture and marketing of products to treat cancer and autoimmune disease.
 -0- 3/31/93
 /CONTACT: Mary McConnon of Immunex, 206-587-0430/
 (IMNX)


CO: Immunex Corp. ST: Washington IN: MTC SU:

LM -- SE015 -- 1639 03/31/93 16:02 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 31, 1993
Words:246
Previous Article:MARITRANS ANNOUNCES CONVERSION TO CORPORATION
Next Article:T/SF COMMUNICATIONS ANNOUNCES FOURTH QUARTER AND FULL YEAR 1992 RESULTS
Topics:


Related Articles
IMMUNEX RECEIVES USE PATENT FOR GM-CSF
IMMUNEX REPORTS 1991 PROFIT; PRODUCT SALES DRIVE COMPANY'S FIRST PROFITABLE YEAR
IMMUNEX OPENS NEW MANUFACTURING AND DEVELOPMENT CENTER
CISTRON BIOTECHNOLOGY SUES IMMUNEX CORP. OVER INTERLEUKIN-1b PATENT
IMMUNEX'S WHITE BLOOD CELL STIMULANT RECOMMENDED FOR TWO NEW INDICATIONS
NEW DATA SHOWS LEUKINE LINKED TO REDUCED INFECTION RATES IN PREMATURE BABIES
Immunex Reports Financial Results
Immunex Reports Third Quarter 1997 Results
Peter Grassam Joins PDL as Vice President, Manufacturing and General Manager Of Plymouth, MN Facility

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters